• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Stepan Reports Second Quarter 2024 Results

    7/31/24 7:00:00 AM ET
    $SCL
    Package Goods/Cosmetics
    Consumer Discretionary
    Get the next $SCL alert in real time by email

    NORTHBROOK, Ill., July 31, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported:

    Stepan Company Logo (PRNewsfoto/Stepan Company)

    Second Quarter 2024 Highlights

    • Reported net income was $9.5 million, down 25% versus prior year. Adjusted net income(1) was $9.4 million, down 22% versus prior year, largely due to a higher effective tax rate in 2024.
    • Pre-tax earnings were negatively impacted by $18.9 million due to higher operating costs at our Millsdale site, primarily related to a flood event ($11.8 million), pre-commissioning expenses at our new Alkoxylation investment in Pasadena, Texas ($3.6 million) and expenses related to a criminal fraud event at a subsidiary in Asia ($3.5 million).
    • EBITDA(2) was $47.9 million and Adjusted EBITDA(2) was $47.7 million, up 3% and 4% respectively, year-over-year.
    • Global sales volume was up 4% year-over-year. Surfactant and Polymer sales volume was up 5% and 2%, respectively.
    • Cash from Operations was $29.5 million during the quarter. Free cash flow(3) for the quarter was slightly negative due to the higher expenses noted above.
    • The Company is on track to deliver its $50 million cost out goal for 2024 and recognized $2.7 million in pre-tax savings, net of the higher operating costs at Millsdale, in the second quarter.

    First Half 2024 Highlights

    • Reported net income was $23.4 million, down 19% versus prior year. Adjusted net income(1) was $24.1 million, down 16% year-over-year, largely due to a higher effective tax rate in 2024.
    • EBITDA(2) was $98.0 million and Adjusted EBITDA(2) was $98.9 million, up 3% and 5% respectively, year-over-year.
    • Global sales volume was up 2% year-over-year. Global sales volume, excluding declines in our Agricultural and commodity Phthalic Anhydride businesses, was up 5%.

    "Second quarter earnings were significantly impacted by higher operational expenses at our Millsdale site, start up costs related to our new Pasadena investment and a criminal social engineering event that targeted one of our Asia subsidiaries, leading to unexpected expense in the quarter.  We are actively investigating this fraud event with the assistance of outside counsel, and to date, we have not found any evidence of additional fraudulent activity," said Scott Behrens, President and Chief Executive Officer.  "From a top line perspective, we continue to be pleased with several of our core markets continuing to deliver volume growth.  Surfactants experienced double-digit volume growth within the Laundry and Cleaning, Construction and Industrial Solutions and Oilfield end markets and also with our Distribution partners.  Latin America Surfactant volumes grew double digits as we recovered Consumer volumes in Mexico and we experienced strong volume growth within several end markets in Brazil, inclusive of double digit Agricultural growth.  North American and European Agricultural volumes remained soft and below our second quarter expectations.  Rigid and Specialty Polyols volumes grew during the quarter.  Global margins were in line with expectations despite unfavorable product mix.  Despite the significant expenses incurred during the quarter, we delivered adjusted EBITDA growth of 4%."

    Financial Summary







    Three Months Ended

    June 30,





    Six Months Ended

    June 30,



    ($ in thousands, except per share data)



    2024





    2023





    %

    Change





    2024





    2023





    %

    Change



    Net Sales



    $

    556,405





    $

    579,975







    (4)

    %



    $

    1,107,823





    $

    1,231,411







    (10)

    %

    Operating Income



    $

    18,667





    $

    17,809







    5

    %



    $

    38,836





    $

    38,866







    (0)

    %

    Net Income



    $

    9,521





    $

    12,684







    (25)

    %



    $

    23,414





    $

    28,826







    (19)

    %

    Earnings per Diluted Share



    $

    0.42





    $

    0.55







    (24)

    %



    $

    1.02





    $

    1.25







    (18)

    %







































    Adjusted Net Income *



    $

    9,396





    $

    12,057







    (22)

    %



    $

    24,052





    $

    28,476







    (16)

    %

    Adjusted Earnings per

       Diluted Share *



    $

    0.41





    $

    0.53







    (23)

    %



    $

    1.05





    $

    1.24







    (15)

    %





    * See Table II for reconciliations of non-GAAP adjusted net income and adjusted earnings per diluted share.



    Percentage Change in Net Sales

    Net sales in the second quarter of 2024 decreased 4% year-over-year primarily due to lower selling prices that were mainly attributable to the pass-through of lower raw material costs and less favorable product mix.  These lower selling prices were partially offset by a 4% increase in global sales volume.





    Three Months Ended

    June 30, 2024





    Six Months Ended

    June 30, 2024



    Volume





    4

    %





    2

    %

    Selling Price & Mix





    (8)

    %





    (13)

    %

    Foreign Translation





    (—)

    %





    1

    %

    Total





    (4)

    %





    (10)

    %

     

    Segment Results









    Three Months Ended

    June 30,





    Six Months Ended

    June 30,



    ($ in thousands)



    2024





    2023





    %

    Change





    2024





    2023





    %

    Change



    Net Sales





































    Surfactants



    $

    379,795





    $

    391,686







    (3)

    %



    $

    770,615





    $

    859,514







    (10)

    %

    Polymers



    $

    159,757





    $

    164,515







    (3)

    %



    $

    305,265





    $

    325,642







    (6)

    %

    Specialty Products



    $

    16,853





    $

    23,774







    (29)

    %



    $

    31,943





    $

    46,255







    (31)

    %

    Total Net Sales



    $

    556,405





    $

    579,975







    (4)

    %



    $

    1,107,823





    $

    1,231,411







    (10)

    %

     





    Three Months Ended

    June 30,





    Six Months Ended

    June 30,



    ($ in thousands, all amounts pre-tax)



    2024





    2023





    %

    Change





    2024





    2023





    %

    Change



    Operating Income





































    Surfactants



    $

    17,062





    $

    15,140







    13

    %



    $

    43,142





    $

    42,196







    2

    %

    Polymers



    $

    13,597





    $

    16,321







    (17)

    %



    $

    21,979





    $

    26,325







    (17)

    %

    Specialty Products



    $

    7,319





    $

    3,773







    94

    %



    $

    11,587





    $

    6,302







    84

    %

    Total Segment

       Operating Income



    $

    37,978





    $

    35,234







    8

    %



    $

    76,708





    $

    74,823







    3

    %

    Corporate Expenses



    $

    (19,311)





    $

    (17,425)







    11

    %



    $

    (37,872)





    $

    (35,957)







    5

    %

    Consolidated

       Operating Income



    $

    18,667





    $

    17,809







    5

    %



    $

    38,836





    $

    38,866







    (0)

    %

     





    Three Months Ended

    June 30,





    Six Months Ended

    June 30,



    ($ in millions)



    2024





    2023





    %

    Change





    2024





    2023





    %

    Change



    EBITDA





































       Surfactants



    $

    35.0





    $

    31.1







    13

    %



    $

    78.6





    $

    73.5







    7

    %

       Polymers



    $

    21.8





    $

    24.6







    (11)

    %



    $

    38.2





    $

    42.9







    (11)

    %

       Specialty Products



    $

    8.8





    $

    5.2







    69

    %



    $

    14.6





    $

    9.1







    60

    %

       Unallocated Corporate



    $

    (17.7)





    $

    (14.2)







    25

    %



    $

    (33.4)





    $

    (30.6)







    9

    %

    Consolidated EBITDA



    $

    47.9





    $

    46.7







    3

    %



    $

    98.0





    $

    94.9







    3

    %







































    Adjusted EBITDA





































       Surfactants



    $

    35.0





    $

    31.0







    13

    %



    $

    78.6





    $

    73.4







    7

    %

       Polymers



    $

    21.8





    $

    24.6







    (11)

    %



    $

    38.2





    $

    42.9







    (11)

    %

       Specialty Products



    $

    8.8





    $

    5.2







    69

    %



    $

    14.6





    $

    9.1







    60

    %

       Unallocated Corporate



    $

    (17.9)





    $

    (15.0)







    19

    %



    $

    (32.5)





    $

    (30.9)







    5

    %

    Consolidated Adjusted EBITDA



    $

    47.7





    $

    45.8







    4

    %



    $

    98.9





    $

    94.5







    5

    %

     

    Consolidated adjusted EBITDA increased $1.9 million, or 4%, year-over-year as a 4% increase in sales volume and slight margin improvement more than offset $11.8 million of negative impact associated with the operational and infrastructure issues at the Millsdale site.  

    • Surfactant net sales were $379.8 million for the quarter, a 3% decrease versus the prior year. Selling prices were down 8% primarily due to the pass-through of lower raw material costs, less favorable product mix and competitive pricing pressures in Latin America. Sales volume was up 5% year-over-year as double digit growth within the Laundry and Cleaning, Construction and Industrial Solutions and Oilfield end markets and with our distribution partners was offset by lower Agricultural demand due to continued customer and channel inventory destocking. Foreign currency translation had a negligible impact on net sales. Surfactant adjusted EBITDA(2) for the quarter increased $4.0 million, or 13%, versus the prior year. This increase was primarily driven by the 5% growth in sales volume and slight margin improvement that was partially offset by pre-operating expenses at the Company's new alkoxylation facility being built in Pasadena, Texas and higher expenses associated with operational and infrastructure issues at the Millsdale plant.



    • Polymer net sales were $159.8 million for the quarter, a 3% decrease versus the prior year. Selling prices decreased 6%, primarily due to the pass-through of lower raw material costs. Sales volume increased 2% in the quarter as a 2% increase in global Rigid Polyols demand and a 28% increase within the Specialty Polyols business was partially offset by lower commodity Phthalic Anhydride volume. Foreign currency translation positively impacted net sales by 1%. Polymer adjusted EBITDA(2) decreased $2.8 million, or 11%, versus the prior year driven by a non-cash Phthalic Anhydride-related catalyst write-off at the Millsdale site and higher costs incurred at Millsdale due to operational and infrastructure issues.



    • Specialty Product net sales were $16.9 million for the quarter, a 29% decrease versus the prior year, primarily due to lower prices. Sales volume was down 2% versus the prior year while adjusted EBITDA(2) increased $3.6 million, or 69%. The increase in adjusted EBITDA(2) was primarily due to higher unit margins within the medium chain triglycerides product line.

    Asia Event

    On July 18, 2024, we determined that a Company subsidiary in Asia had been the victim of a criminal social engineering scheme which resulted in fraudulently induced outbound payments.  The Company immediately launched an investigation, led by outside counsel, to determine the full extent of the fraud scheme and related potential exposure.  The investigation is ongoing.  We initiated contact with our banks and law enforcement authorities in an effort to, among other things, recover the transferred funds.  We have not found any evidence of additional fraudulent activity and we believe this is an isolated and contained event.  This incident did not result in any unauthorized access to our information systems or any confidential customer information or other data that we maintain. The Company has recognized a $3.5 million pre-tax charge for the quarter ended June 30, 2024, and, while the investigation is ongoing, the Company expects to record a charge in a similar amount in the third quarter of 2024 as a result of this event. While this matter will result in some additional near-term expenses, the Company does not expect this incident to otherwise have a material impact on its business. 

    Outlook

    "We expect second half EBITDA to improve versus the prior year based on continued volume growth and a significant reduction in second half operational expenses at our Millsdale site, which was the majority of the significant variance in second quarter expenses.   The on-going recovery in Rigid Polyols and the expected second half of the year recovery of the Agricultural Chemicals business should drive improved earnings," said Scott Behrens, President and Chief Executive Officer.  "Free cash flow should continue to improve versus prior year driven by the completion of our Pasadena investment, the growth in market volumes, and our continued focus on cost reduction.   We believe we are positioned to deliver full year Adjusted EBITDA growth and positive free cash flow."

    Notes

    (1) Adjusted net income and adjusted earnings per share are non-GAAP measures which exclude deferred compensation income/expense, cash-settled stock appreciation rights (SARs) income/expense, certain environmental remediation-related costs as well as other significant and infrequent/non-recurring items. See Table II for reconciliations of non-GAAP adjusted net income and adjusted earnings per diluted share.



    (2) EBITDA and adjusted EBITDA are non-GAAP measures.  See Table VI for calculations and GAAP reconciliations of EBITDA and adjusted EBITDA.



    (3) Free Cash Flow is a non-GAAP measure and reflects cash generated from operations minus capital expenditures.



    Conference Call

    Stepan Company will host a conference call to discuss its second quarter results at 9:00 a.m. ET (8:00 a.m. CT) on July 31, 2024. The call can be accessed by phone and webcast. To access the call by phone, please click on this Registration Link, complete the form and you will be provided with dial in details and a PIN.  To avoid delays, we encourage participants to dial into the conference call ten minutes ahead of the scheduled start time.  The webcast can be accessed through the Investors/Conference Calls page at www.stepan.com. A webcast replay of the conference call will be available at the same location shortly after the call.

    Supporting Slides

    Slides supporting this press release will be made available at www.stepan.com through the Investors/Presentations page at approximately the same time as this press release is issued.

    Corporate Profile

    Stepan Company is a major manufacturer of specialty and intermediate chemicals used in a broad range of industries. Stepan is a leading merchant producer of surfactants, which are the key ingredients in consumer and industrial cleaning and disinfection compounds and in agricultural and oilfield solutions. The Company is also a leading supplier of polyurethane polyols used in the expanding thermal insulation market, and CASE (Coatings, Adhesives, Sealants, and Elastomers) industries.

    Headquartered in Northbrook, Illinois, Stepan utilizes a network of modern production facilities located in North and South America, Europe and Asia. 

    The Company's common stock is traded on the New York Stock Exchange (NYSE) under the symbol SCL. For more information about Stepan Company please visit the Company online at www.stepan.com 

    More information about Stepan's sustainability program can be found on the Sustainability page at www.stepan.com 

    Certain information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements about Stepan Company's plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, Stepan Company's actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "guidance," "predict," "potential," "continue," "likely," "will," "would," "should," "illustrative" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Stepan Company and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements.

    There are a number of risks, uncertainties and other important factors, many of which are beyond Stepan Company's control, that could cause actual results to differ materially from the forward-looking statements contained in this news release. Such risks, uncertainties and other important factors include, among other factors, the risks, uncertainties and factors described in Stepan Company's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports, and include (but are not limited to) risks and uncertainties related to  accidents, unplanned production shutdowns or disruptions in manufacturing facilities; reduced demand due to customer product reformulations or new technologies; our inability to successfully develop or introduce new products; compliance with laws; our ability to identify suitable acquisition candidates and successfully complete and integrate acquisitions; global competition; volatility of raw material and energy costs and supply; disruptions in transportation or significant changes in transportation costs; downturns in certain industries and general economic downturns; international business risks, including currency exchange rate fluctuations, legal restrictions and taxes; unfavorable resolution of litigation against us; maintaining and protecting intellectual property rights; our ability to access capital markets; global political, military, security or other instability; costs related to expansion or other capital projects; interruption or breaches of information technology systems; our ability to retain executive management and key personnel; and our debt covenants.

    These forward-looking statements are made only as of the date hereof, and Stepan Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

    * * * * *

    Tables follow

    Table I

    STEPAN COMPANY

    For the Three and Six Months Ended June 30, 2024 and 2023

    (Unaudited – in 000's, except per share data)







    Three Months Ended

    June 30,





    Six Months Ended

    June 30,







    2024





    2023





    2024





    2023



    Net Sales



    $

    556,405





    $

    579,975





    $

    1,107,823





    $

    1,231,411



    Cost of Sales





    486,853







    513,578







    967,990







    1,091,454



    Gross Profit





    69,552







    66,397







    139,833







    139,957



    Operating Expenses:

























    Selling





    11,828







    11,109







    23,216







    24,176



    Administrative





    24,569







    22,589







    47,259







    45,228



    Research, Development and Technical Services





    14,093







    14,105







    28,349







    29,243



    Deferred Compensation Expense





    395







    743







    2,173







    2,245









    50,885







    48,546







    100,997







    100,892





























    Business Restructuring Expense





    -







    42







    -







    199





























    Operating Income





    18,667







    17,809







    38,836







    38,866





























    Other Income (Expense):

























    Interest, Net





    (2,661)







    (3,865)







    (5,732)







    (6,687)



    Other, Net





    1,200







    2,370







    3,562







    4,038









    (1,461)







    (1,495)







    (2,170)







    (2,649)





























    Income Before Provision for Income Taxes





    17,206







    16,314







    36,666







    36,217



    Provision for Income Taxes





    7,685







    3,630







    13,252







    7,391



    Net Income





    9,521







    12,684







    23,414







    28,826



    Net Income Per Common Share

























    Basic



    $

    0.42





    $

    0.56





    $

    1.03





    $

    1.27



    Diluted



    $

    0.42





    $

    0.55





    $

    1.02





    $

    1.25



    Shares Used to Compute Net Income Per

       Common Share

























    Basic





    22,827







    22,768







    22,825







    22,763



    Diluted





    22,936







    22,945







    22,942







    22,970



     

    Table II

    Reconciliation of Non-GAAP Net Income and Earnings per Diluted Share*







    Three Months Ended

    June 30,





    Six Months Ended

    June 30,



    ($ in thousands, except per share amounts)



    2024





    EPS





    2023





    EPS





    2024





    EPS





    2023





    EPS



    Net Income Reported



    $

    9,521





    $

    0.42





    $

    12,684





    $

    0.55





    $

    23,414





    $

    1.02





    $

    28,826





    $

    1.25





















































    Deferred Compensation

       Income



    $

    (305)





    $

    (0.01)





    $

    (653)





    $

    (0.02)





    $

    (693)





    $

    (0.03)





    $

    (757)





    $

    (0.03)



    Business Restructuring Expense



    $

    -





    $

    -





    $

    31





    $

    -





    $

    -





    $

    -





    $

    146





    $

    0.01



    Cash-Settled SARs Income



    $

    -





    $

    -





    $

    (44)





    $

    -





    $

    -





    $

    -





    $

    (84)





    $

    -



    Environmental Remediation

        Expense



    $

    180





    $

    -





    $

    39





    $

    -





    $

    1,331





    $

    0.06





    $

    345





    $

    0.01



    Adjusted Net Income



    $

    9,396





    $

    0.41





    $

    12,057





    $

    0.53





    $

    24,052





    $

    1.05





    $

    28,476





    $

    1.24







    *

    All amounts in this table are presented after-tax

    The Company believes that certain non-GAAP measures, in conjunction with comparable GAAP measures, are useful for evaluating the Company's operating performance and financial condition.  The Company uses this non-GAAP information as an indicator of business performance and evaluates management's effectiveness with specific reference to these indicators.  Management believes that these non-GAAP financial measures provide useful supplemental information because they exclude non-operational items that affect comparability between years.  These measures should be considered in addition to, not as substitutes for or superior to, measures of financial performance prepared in accordance with GAAP and may differ from similarly titled measures presented by other companies.  The Company's Annual Report on Form 10-K for the year ended December 31, 2023 contains additional information regarding the use of non-GAAP financial measures.

    Summary of Second Quarter 2024 Adjusted Net Income Items

    Adjusted net income excludes non-operational deferred compensation income/expense, cash-settled SARs income/expense, certain environmental remediation costs and other significant and infrequent or non-recurring items.

    • Deferred Compensation: The second quarter of 2024 reported net income includes $0.3 million of after-tax income versus $0.7 million of after-tax income in the prior year.



    • Environmental Remediation – The second quarter of 2024 reported net income includes $0.2 million of after-tax expense versus less than $0.1 million of after-tax expense in the prior year.

    Table III

    Reconciliation of Pre-Tax to After-Tax Adjustments



    Management uses the non-GAAP adjusted net income metric to evaluate the Company's operating performance.  Management excludes the items listed in the table below because they are non-operational items.  The cumulative tax effect was calculated using the statutory tax rates for the jurisdictions in which the transactions occurred.







    Three Months Ended

    June 30,





    Six Months Ended

    June 30,



    ($ in thousands, except per share amounts)



    2024





    EPS





    2023





    EPS





    2024





    EPS





    2023





    EPS



    Pre-Tax Adjustments

















































    Deferred Compensation

        Income



    $

    (407)











    $

    (871)











    $

    (924)











    $

    (1,009)









    Business Restructuring Expense



    $

    -











    $

    42











    $

    -











    $

    199









    Cash-Settled SARs Income



    $

    -











    $

    (58)











    $

    -











    $

    (111)









    Environmental Remediation

        Expense



    $

    240











    $

    52











    $

    1,774











    $

    461









       Total Pre-Tax Adjustments



    $

    (167)











    $

    (835)











    $

    850











    $

    (460)



























































    Cumulative Tax Effect

        on Adjustments



    $

    42











    $

    208











    $

    (212)











    $

    110



























































    After-Tax Adjustments



    $

    (125)





    $

    -





    $

    (627)





    $

    (0.02)





    $

    638





    $

    0.03





    $

    (350)





    $

    (0.01)





































































     

    Table IV

    Deferred Compensation Plans



    The full effect of the deferred compensation plans on quarterly pre-tax income was $0.4 million of income versus $0.9 million of income in the prior year.  The quarter-end market prices of Company stock and the impact of deferred compensation on specific income statement line items is summarized below:







    2024





    2023







    6/30





    3/31





    12/31





    9/30





    6/30





    3/31



    Stepan Company



    $

    83.96





    $

    90.04





    $

    94.55





    $

    74.97





    $

    95.56





    $

    103.03





















































     





    Three Months Ended

    June 30,





    Six Months Ended

    June 30,



    ($ in thousands)



    2024





    2023





    2024





    2023



    Deferred Compensation

























    Operating Expense



    $

    (395)





    $

    (743)





    $

    (2,173)





    $

    (2,245)



    Other, net – Mutual Fund Gain





    802







    1,614







    3,097







    3,254



    Total Pre-Tax



    $

    407





    $

    871





    $

    924





    $

    1,009



    Total After-Tax



    $

    305





    $

    653





    $

    693





    $

    757



     

    Effects of Foreign Currency Translation 



    The Company's foreign subsidiaries transact business and report financial results in their respective local currencies. These results are translated into U.S. dollars at average foreign exchange rates appropriate for the reporting period.  The table below presents the impact that foreign currency translation had on select income statement line items.  



    ($ in millions)



    Three Months Ended

    June 30,





    Change





    Change

    Due to

    Foreign

    Currency

    Translation





    Six Months Ended

    June 30,





    Change





    Change

    Due to

    Foreign

    Currency

    Translation







    2024





    2023

















    2024





    2023















    Net Sales



    $

    556.4





    $

    580.0





    $

    (23.6)





    $

    0.8





    $

    1,107.8





    $

    1,231.4





    $

    (123.6)





    $

    12.6



    Gross Profit





    69.6







    66.4





    $

    3.2







    (0.2)







    139.8







    140.0





    $

    (0.2)







    1.1



    Operating Income





    18.7







    17.8





    $

    0.9







    -







    38.8







    38.9





    $

    (0.1)







    0.6



    Pretax Income





    17.2







    16.3





    $

    0.9







    (0.1)







    36.7







    36.2





    $

    0.5







    0.5



     

    Corporate Expenses







    Three Months Ended

    June 30,





    Six Months Ended

    June 30,



    ($ in thousands)



    2024





    2023





    %

    Change





    2024





    2023





    %

    Change



    Total Corporate Expenses



    $

    19,311





    $

    17,424







    11

    %



    $

    37,872





    $

    35,957







    5

    %

    Less:





































       Deferred Compensation Expense



    $

    395





    $

    743







    (47)

    %



    $

    2,173





    $

    2,245







    (3)

    %

       Business Restructuring Expense



    $

    -





    $

    42







    (100)

    %



    $

    -





    $

    199







    (100)

    %

       Environmental Remediation

          Expense



    $

    240





    $

    52







    362

    %



    $

    1,774





    $

    461







    285

    %

    Adjusted Corporate Expenses



    $

    18,676





    $

    16,587







    13

    %



    $

    33,925





    $

    33,052







    3

    %

    Adjusted Corporate expenses increased $2.1 million, or 13% for the quarter. This increase was primarily due to $3.5 million of higher expenses associated with a criminal social engineering scheme at one of the Company's subsidiaries in Asia, partially offset by productivity measures implemented in late 2023.

     

    Table V

    Stepan Company

    Consolidated Balance Sheets

    June 30, 2024 and December 31, 2023







    June 30, 2024





    December 31,

    2023



    ASSETS













    Current Assets



    $

    867,140





    $

    851,883



    Property, Plant & Equipment, Net





    1,195,117







    1,206,665



    Other Assets





    286,333







    304,806



    Total Assets



    $

    2,348,590





    $

    2,363,354



    LIABILITIES AND STOCKHOLDERS' EQUITY













    Current Liabilities



    $

    655,195





    $

    607,870



    Deferred Income Taxes





    10,224







    10,373



    Long-term Debt





    374,708







    401,248



    Other Non-current Liabilities





    116,027







    127,373



    Total Stepan Company Stockholders' Equity





    1,192,436







    1,216,490



    Total Liabilities and Stockholders' Equity



    $

    2,348,590





    $

    2,363,354



     

    Selected Balance Sheet Information 



    The Company's total debt increased by $11.1 million and cash decreased by $1.1 million versus March 31, 2024.  The increase in debt primarily reflects higher borrowings against the Company's revolving credit facility that were partially offset by scheduled debt repayments.  The Company's net debt level increased $12.2 million versus March 31, 2024 and the net debt ratio increased from 30% to 31% in the quarter (Net Debt and Net Debt Ratios are non-GAAP measures, reconciliations of which are shown in the table below).  Management uses the non-GAAP net debt metric to show a more complete picture of the Company's overall liquidity, financial flexibility and leverage level.  



    ($ in millions)



    June 30, 2024





    March 31, 2024





    December 31,

    2023



    Net Debt



















    Total Debt



    $

    657.1





    $

    646.0





    $

    654.1



    Cash





    124.7







    125.8







    129.8



    Net Debt



    $

    532.4





    $

    520.2





    $

    524.3



    Equity





    1,192.4







    1,214.5







    1,216.5



    Net Debt + Equity



    $

    1,724.8





    $

    1,734.7





    $

    1,740.8



    Net Debt / (Net Debt + Equity)





    31

    %





    30

    %





    30

    %

     

    The major working capital components were: 



    ($ in millions)



    June 30, 2024





    March 31, 2024





    December 31, 2023



    Net Receivables



    $

    437.3





    $

    446.6





    $

    422.1



    Inventories





    266.0







    257.1







    265.6



    Accounts Payable





    (251.2)







    (256.9)







    (233.0)







    $

    452.1





    $

    446.8





    $

    454.7



     

    Table VI 

    Reconciliations of Non-GAAP EBITDA and Adjusted EBITDA to Operating Income



    Management uses the non-GAAP EBITDA and adjusted EBITDA metrics to evaluate the Company's operating performance.  Management excludes the items listed in the table below because they are non-operational items.







    Three Months Ended

    June 30, 2024



































    ($ in millions)



    Surfactants





    Polymers





    Specialty

    Products





    Unallocated

    Corporate





    Consolidated



    Operating Income



    $

    17.1





    $

    13.6





    $

    7.3





    $

    (19.3)





    $

    18.7



       Depreciation and Amortization



    $

    17.9





    $

    8.2





    $

    1.5





    $

    0.4





    $

    28.0



       Other, Net Income



    $

    -





    $

    -





    $

    -





    $

    1.2





    $

    1.2



    EBITDA



    $

    35.0





    $

    21.8





    $

    8.8





    $

    (17.7)





    $

    47.9



       Deferred Compensation



    $

    -





    $

    -





    $

    -





    $

    (0.4)





    $

    (0.4)



       Environmental Remediation



    $

    -





    $

    -





    $

    -





    $

    0.2





    $

    0.2



    Adjusted EBITDA



    $

    35.0





    $

    21.8





    $

    8.8





    $

    (17.9)





    $

    47.7







































    Three Months Ended

    June 30, 2023



































    ($ in millions)



    Surfactants





    Polymers





    Specialty

    Products





    Unallocated

    Corporate





    Consolidated



    Operating Income



    $

    15.1





    $

    16.3





    $

    3.8





    $

    (17.4)





    $

    17.8



       Depreciation and Amortization



    $

    16.0





    $

    8.3





    $

    1.4





    $

    0.8





    $

    26.5



       Other, Net Income



    $

    -





    $

    -





    $

    -





    $

    2.4





    $

    2.4



    EBITDA



    $

    31.1





    $

    24.6





    $

    5.2





    $

    (14.2)





    $

    46.7



       Deferred Compensation



    $

    -





    $

    -





    $

    -





    $

    (0.9)





    $

    (0.9)



       Cash Settled SARs



    $

    (0.1)





    $

    -





    $

    -





    $

    -





    $

    (0.1)



       Business Restructuring



    $

    -





    $

    -





    $

    -





    $

    -





    $

    -



       Environmental Remediation



    $

    -





    $

    -





    $

    -





    $

    0.1





    $

    0.1



    Adjusted EBITDA



    $

    31.0





    $

    24.6





    $

    5.2





    $

    (15.0)





    $

    45.8















    Six Months Ended

    June 30, 2024



































    ($ in millions)



    Surfactants





    Polymers





    Specialty

    Products





    Unallocated

    Corporate





    Consolidated



    Operating Income



    $

    43.1





    $

    22.0





    $

    11.6





    $

    (37.9)





    $

    38.8



       Depreciation and Amortization



    $

    35.5





    $

    16.2





    $

    3.0





    $

    0.9





    $

    55.6



       Other, Net Income



    $

    -





    $

    -





    $

    -





    $

    3.6





    $

    3.6



    EBITDA



    $

    78.6





    $

    38.2





    $

    14.6





    $

    (33.4)





    $

    98.0



       Deferred Compensation



    $

    -





    $

    -





    $

    -





    $

    (0.9)





    $

    (0.9)



       Environmental Remediation



    $

    -





    $

    -





    $

    -





    $

    1.8





    $

    1.8



    Adjusted EBITDA



    $

    78.6





    $

    38.2





    $

    14.6





    $

    (32.5)





    $

    98.9







































    Six Months Ended

    June 30, 2023



































    ($ in millions)



    Surfactants





    Polymers





    Specialty

    Products





    Unallocated

    Corporate





    Consolidated



    Operating Income



    $

    42.2





    $

    26.3





    $

    6.3





    $

    (35.9)





    $

    38.9



       Depreciation and Amortization



    $

    31.3





    $

    16.6





    $

    2.8





    $

    1.3





    $

    52.0



       Other, Net Income (Expense)



    $

    -





    $

    -





    $

    -





    $

    4.0





    $

    4.0



    EBITDA



    $

    73.5





    $

    42.9





    $

    9.1





    $

    (30.6)





    $

    94.9



       Deferred Compensation



    $

    -





    $

    -





    $

    -





    $

    (1.0)





    $

    (1.0)



       Cash Settled SARs



    $

    (0.1)





    $

    -





    $

    -





    $

    -





    $

    (0.1)



       Business Restructuring



    $

    -





    $

    -





    $

    -





    $

    0.2





    $

    0.2



       Environmental Remediation



    $

    -





    $

    -





    $

    -





    $

    0.5





    $

    0.5



    Adjusted EBITDA



    $

    73.4





    $

    42.9





    $

    9.1





    $

    (30.9)





    $

    94.5



     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/stepan-reports-second-quarter-2024-results-302210820.html

    SOURCE Stepan Company

    Get the next $SCL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SCL

    DatePrice TargetRatingAnalyst
    10/19/2023$89.00Neutral → Buy
    CL King
    3/11/2022$9.00 → $8.00Outperform
    RBC Capital
    12/20/2021$8.50 → $9.00Outperform
    RBC Capital
    More analyst ratings

    $SCL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Stepan Reports First Quarter 2025 Results

      NORTHBROOK, Ill., April 29, 2025 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: First Quarter 2025 Highlights Reported net income was $19.7 million, up 42% versus the prior year. Adjusted net income(1) was $19.3 million, up 32% versus the prior year.EBITDA(2) was $58.0 million and Adjusted EBITDA(2) was $57.5 million, up 16% and 12% respectively, year-over-year.Global sales volume was up 4% year-over-year.Cash from Operations was $6.9 million during the quarter. Free cash flow(3) for the quarter was a negative $25.8 million driven by higher working capital to suppor

      4/29/25 7:00:00 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • Stepan Declares Quarterly Dividend

      NORTHBROOK, Ill., April 29, 2025 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: The Board of Directors of Stepan Company has declared a quarterly cash dividend on the Company's common stock of $0.385 per share. The dividend is payable on June 13, 2025, to common stockholders of record on May 30, 2025. The Company increased its quarterly cash dividend in the fourth quarter of 2024 by $0.010 per share, marking the 57th consecutive year that the Company has increased its cash dividend to stockholders. Corporate Profile Stepan Company is a major manufacturer of specialt

      4/29/25 7:00:00 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • Stepan to Announce First Quarter 2025 Results on April 29, 2025

      NORTHBROOK, Ill., April 14, 2025 /PRNewswire/ -- Stepan Company (NYSE:SCL) will issue its first quarter 2025 earnings results on Tuesday, April 29, 2025 at approximately 7:00 a.m. ET (6:00 a.m. CT). Supporting slides will be posted at approximately the same time on the Investors/Presentations page at www.stepan.com. The Company will hold a conference call to discuss and answer questions about its financial and operational performance on the same day at 8:00 a.m. ET (7:00 a.m. CT). The call will be hosted by Luis E. Rojo, President and Chief Executive Officer, and Samuel S. Hin

      4/14/25 7:00:00 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary

    $SCL
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Stepan Company

      SCHEDULE 13G - STEPAN CO (0000094049) (Subject)

      5/13/25 12:17:58 PM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • SEC Form 10-Q filed by Stepan Company

      10-Q - STEPAN CO (0000094049) (Filer)

      5/7/25 10:15:10 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • Stepan Company filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - STEPAN CO (0000094049) (Filer)

      5/5/25 7:00:08 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary

    $SCL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Stepan Company upgraded by CL King with a new price target

      CL King upgraded Stepan Company from Neutral to Buy and set a new price target of $89.00

      10/19/23 9:02:32 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • RBC Capital reiterated coverage on Shawcor with a new price target

      RBC Capital reiterated coverage of Shawcor with a rating of Outperform and set a new price target of $8.00 from $9.00 previously

      3/11/22 7:14:07 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • RBC Capital reiterated coverage on Shawcor with a new price target

      RBC Capital reiterated coverage of Shawcor with a rating of Outperform and set a new price target of $9.00 from $8.50 previously

      12/20/21 6:55:29 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary

    $SCL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Supply Chain Haire Robert Joseph exercised 550 shares at a strike of $51.85 and covered exercise/tax liability with 162 shares, increasing direct ownership by 52% to 1,141 units (SEC Form 4)

      4 - STEPAN CO (0000094049) (Issuer)

      5/5/25 6:06:02 PM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • Director Wehmer Edward J exercised 1,865 shares at a strike of $48.07, increasing direct ownership by 33% to 7,449 units (SEC Form 4)

      4 - STEPAN CO (0000094049) (Issuer)

      4/15/25 4:10:31 PM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • SEC Form 4 filed by Director Wehmer Edward J

      4 - STEPAN CO (0000094049) (Issuer)

      4/3/25 4:30:39 PM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary

    $SCL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lewis Susan bought $31,765 worth of shares (500 units at $63.53), increasing direct ownership by 36% to 1,896 units (SEC Form 4)

      4 - STEPAN CO (0000094049) (Issuer)

      2/27/25 8:57:39 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • VP GC & Secretary Kabbes David bought $75,388 worth of shares (1,056 units at $71.39) (SEC Form 4)

      4 - STEPAN CO (0000094049) (Issuer)

      8/15/24 1:19:55 PM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary

    $SCL
    Financials

    Live finance-specific insights

    See more
    • Stepan Reports First Quarter 2025 Results

      NORTHBROOK, Ill., April 29, 2025 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: First Quarter 2025 Highlights Reported net income was $19.7 million, up 42% versus the prior year. Adjusted net income(1) was $19.3 million, up 32% versus the prior year.EBITDA(2) was $58.0 million and Adjusted EBITDA(2) was $57.5 million, up 16% and 12% respectively, year-over-year.Global sales volume was up 4% year-over-year.Cash from Operations was $6.9 million during the quarter. Free cash flow(3) for the quarter was a negative $25.8 million driven by higher working capital to suppor

      4/29/25 7:00:00 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • Stepan Declares Quarterly Dividend

      NORTHBROOK, Ill., April 29, 2025 /PRNewswire/ -- Stepan Company (NYSE:SCL) today reported: The Board of Directors of Stepan Company has declared a quarterly cash dividend on the Company's common stock of $0.385 per share. The dividend is payable on June 13, 2025, to common stockholders of record on May 30, 2025. The Company increased its quarterly cash dividend in the fourth quarter of 2024 by $0.010 per share, marking the 57th consecutive year that the Company has increased its cash dividend to stockholders. Corporate Profile Stepan Company is a major manufacturer of specialt

      4/29/25 7:00:00 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • Stepan to Announce First Quarter 2025 Results on April 29, 2025

      NORTHBROOK, Ill., April 14, 2025 /PRNewswire/ -- Stepan Company (NYSE:SCL) will issue its first quarter 2025 earnings results on Tuesday, April 29, 2025 at approximately 7:00 a.m. ET (6:00 a.m. CT). Supporting slides will be posted at approximately the same time on the Investors/Presentations page at www.stepan.com. The Company will hold a conference call to discuss and answer questions about its financial and operational performance on the same day at 8:00 a.m. ET (7:00 a.m. CT). The call will be hosted by Luis E. Rojo, President and Chief Executive Officer, and Samuel S. Hin

      4/14/25 7:00:00 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary

    $SCL
    Leadership Updates

    Live Leadership Updates

    See more
    • Stepan Promotes Luis E. Rojo to President and Chief Executive Officer

      NORTHBROOK, Ill., Oct. 30, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) today announced the appointment of Luis E. Rojo as President and Chief Executive Officer and as a member of the Board of Directors, effective immediately. After a 31-year Stepan career, Scott R. Behrens is departing the Company to pursue other opportunities. "We thank Scott for his leadership and his many contributions to the growth and diversification of Stepan over his career with the Company. During his various roles in R&D, sales and marketing, and leadership, he helped diversify our market presence,

      10/30/24 6:55:00 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • Stepan Company Announces Appointment of New Director

      NORTHBROOK, Ill., Feb. 15, 2024 /PRNewswire/ -- Stepan Company (NYSE:SCL) announced today the appointment of Susan M. Lewis as a Director of Stepan, effective on February 15, 2024. Ms. Lewis spent over 30 years at Dow Inc., a materials science company, and was part of the management team of Corteva, Inc., a global agriculture company, following its spinoff from DowDuPont Inc. Ms. Lewis served as Senior Vice President, Global Operations of Corteva from 2018 until her retirement in 2021, after which she worked as a business and executive consultant through 2023. Ms. Lewis held senior management roles with operations, sustainability and risk management responsibilities and led organizational r

      2/15/24 4:30:00 PM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • AVITA Medical, Inc. Appoints Two New Non-Executive Members to the Board of Directors

      VALENCIA, Calif. and MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))) ("AVITA Medical"), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of James Corbett and Jan Stern Reed to its Board of Directors effective July 1, 2021. Mr. Corbett has approximately 40 years of leadership experience in the medical device field, most recently, as CEO of CathWorks Ltd., a software-based medical technology company. Mr. Corbett has extensive global commercial and operating experience, serving as an

      6/1/21 4:01:00 PM ET
      $SCL
      $RCEL
      $ANGO
      Package Goods/Cosmetics
      Consumer Discretionary
      Medical/Dental Instruments
      Health Care

    $SCL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Stepan Company

      SC 13G - STEPAN CO (0000094049) (Subject)

      2/9/24 9:59:18 AM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Stepan Company (Amendment)

      SC 13G/A - STEPAN CO (0000094049) (Subject)

      1/24/24 12:33:12 PM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary
    • SEC Form SC 13G/A filed by Stepan Company (Amendment)

      SC 13G/A - STEPAN CO (0000094049) (Subject)

      1/22/24 3:52:11 PM ET
      $SCL
      Package Goods/Cosmetics
      Consumer Discretionary